Genscript Biotech: Associate “Legend” Books US$710.00 Million Net Trade Sales for CARVYKTI® in Q3 2026

Bulletin Express

3 hours ago

Genscript Biotech Corporation (HKEX: 01548) disclosed that its U.S.–listed associate, Legend Biotech Corporation (“Legend”), recorded approximately US$710.00 million in net trade sales of CARVYKTI® for the quarter ended 30 September 2026. The figure was communicated by Janssen Biotech, Inc. to Legend under their December 2017 Collaboration and License Agreement and was reported by Legend in a Form 6-K filed with the U.S. Securities and Exchange Commission on 13 October 2026 (New York time).

The latest sales number follows earlier disclosures for the first and second quarters of 2026 and highlights continued commercial traction for the BCMA-directed CAR-T therapy. Genscript noted that neither it nor Legend has independently verified the sales data provided by Janssen.

Management reiterated customary forward-looking statement cautions, citing regulatory developments, clinical outcomes, competitive dynamics, and intellectual-property considerations as key variables that could influence future performance.

Investors are advised to remain aware of the inherent risks associated with forward-looking information when evaluating the Company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigermarketd.com/news/1147533477"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147533477\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147533477?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-13 20:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147533477","market":"hk","top_or_hot":-1,"title":"Genscript Biotech: Associate “Legend” Books US$710.00 Million Net Trade Sales for CARVYKTI® in Q3 2026","media":"Bulletin Express","content":"<p>Genscript Biotech Corporation (HKEX: 01548) disclosed that its U.S.–listed associate, Legend Biotech Corporation (“Legend”), recorded approximately US$710.00 million in net trade sales of CARVYKTI® for the quarter ended 30 September 2026. The figure was communicated by Janssen Biotech, Inc. to Legend under their December 2017 Collaboration and License Agreement and was reported by Legend in a Form 6-K filed with the U.S. Securities and Exchange Commission on 13 October 2026 (New York time).</p>\n<p>The latest sales number follows earlier disclosures for the first and second quarters of 2026 and highlights continued commercial traction for the BCMA-directed CAR-T therapy. Genscript noted that neither it nor Legend has independently verified the sales data provided by Janssen.</p>\n<p>Management reiterated customary forward-looking statement cautions, citing regulatory developments, clinical outcomes, competitive dynamics, and intellectual-property considerations as key variables that could influence future performance.</p>\n<p>Investors are advised to remain aware of the inherent risks associated with forward-looking information when evaluating the Company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript Biotech: Associate “Legend” Books US$710.00 Million Net Trade Sales for CARVYKTI® in Q3 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript Biotech: Associate “Legend” Books US$710.00 Million Net Trade Sales for CARVYKTI® in Q3 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-10-13 20:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genscript Biotech Corporation (HKEX: 01548) disclosed that its U.S.–listed associate, Legend Biotech Corporation (“Legend”), recorded approximately US$710.00 million in net trade sales of CARVYKTI® for the quarter ended 30 September 2026. The figure was communicated by Janssen Biotech, Inc. to Legend under their December 2017 Collaboration and License Agreement and was reported by Legend in a Form 6-K filed with the U.S. Securities and Exchange Commission on 13 October 2026 (New York time).</p>\n<p>The latest sales number follows earlier disclosures for the first and second quarters of 2026 and highlights continued commercial traction for the BCMA-directed CAR-T therapy. Genscript noted that neither it nor Legend has independently verified the sales data provided by Janssen.</p>\n<p>Management reiterated customary forward-looking statement cautions, citing regulatory developments, clinical outcomes, competitive dynamics, and intellectual-property considerations as key variables that could influence future performance.</p>\n<p>Investors are advised to remain aware of the inherent risks associated with forward-looking information when evaluating the Company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1147533477","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147533477","pubTimestamp":1791895289,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Genscript Biotech Corporation (HKEX: 01548) disclosed that its U.S.–listed associate, Legend Biotech Corporation (“Legend”), recorded approximately US$710.00 million in net trade sales of CARVYKTI®...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞生物科技：合作伙伴“传奇”Books CARVYKTI 实现 7.1 亿美元净贸易销售额®2026年第三季度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Genscript Biotech Corporation (HKEX: 01548) disclosed that its U.S.–listed associate, Legend Biotech Corporation (“Legend”), recorded approximately US$710.00 million in net trade sales of CARVYKTI® for the quarter ended 30 September 2026. The figure was communicated by Janssen Biotech, Inc. to Legend under their December 2017 Collaboration and License Agreement and was reported by Legend in a Form 6-K filed with the U.S. Securities and Exchange Commission on 13 October 2026 (New York time).\nThe latest sales number follows earlier disclosures for the first and second quarters of 2026 and highlights continued commercial traction for the BCMA-directed CAR-T therapy. Genscript noted that neither it nor Legend has independently verified the sales data provided by Janssen.\nManagement reiterated customary forward-looking statement cautions, citing regulatory developments, clinical outcomes, competitive dynamics, and intellectual-property considerations as key variables that could influence future performance.\nInvestors are advised to remain aware of the inherent risks associated with forward-looking information when evaluating the Company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}